WO2021043340A3 - 一种肿瘤标志物aquaporin 2蛋白及其应用 - Google Patents

一种肿瘤标志物aquaporin 2蛋白及其应用 Download PDF

Info

Publication number
WO2021043340A3
WO2021043340A3 PCT/CN2020/126029 CN2020126029W WO2021043340A3 WO 2021043340 A3 WO2021043340 A3 WO 2021043340A3 CN 2020126029 W CN2020126029 W CN 2020126029W WO 2021043340 A3 WO2021043340 A3 WO 2021043340A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumour
protein
aquaporin
inhibiting
application
Prior art date
Application number
PCT/CN2020/126029
Other languages
English (en)
French (fr)
Other versions
WO2021043340A2 (zh
Inventor
徐寒梅
李梦玮
Original Assignee
南京安吉生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南京安吉生物科技有限公司 filed Critical 南京安吉生物科技有限公司
Priority to AU2020342299A priority Critical patent/AU2020342299B2/en
Priority to CA3169749A priority patent/CA3169749A1/en
Priority to EP20859995.1A priority patent/EP4006166A4/en
Priority to US17/640,380 priority patent/US20220299516A1/en
Priority to JP2022514787A priority patent/JP7323965B2/ja
Publication of WO2021043340A2 publication Critical patent/WO2021043340A2/zh
Publication of WO2021043340A3 publication Critical patent/WO2021043340A3/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)

Abstract

本发明公开了一种肿瘤标志物AQUAPORIN 2蛋白及其应用，属于肿瘤检测和分子靶向治疗领域。本发明包括AQUAPORIN 2蛋白在如下功能中的应用：(1)作为新的肿瘤标志物用于包括头颈鳞癌、肾癌和前列腺癌在内的恶性肿瘤的早期诊断及预后效果的判定；(2)抑制肿瘤细胞增殖；(3)抑制肿瘤细胞迁移；(4)抑制动物移植瘤模型的生长；本发明以AQUAPORIN 2蛋白作为生物标志物的靶向疗法为头颈鳞癌、肾癌和前列腺癌等恶性肿瘤的治疗提供新的思路。
PCT/CN2020/126029 2019-09-05 2020-11-03 一种肿瘤标志物aquaporin 2蛋白及其应用 WO2021043340A2 (zh)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2020342299A AU2020342299B2 (en) 2019-09-05 2020-11-03 Tumour marker aquaporin 2 protein and application thereof
CA3169749A CA3169749A1 (en) 2019-09-05 2020-11-03 Tumor marker aquaporin 2 protein and application thereof
EP20859995.1A EP4006166A4 (en) 2019-09-05 2020-11-03 AQUAPORIN 2 TUMOR MARKER PROTEIN AND ITS APPLICATION
US17/640,380 US20220299516A1 (en) 2019-09-05 2020-11-03 Tumor marker aquaporin 2 protein and application thereof
JP2022514787A JP7323965B2 (ja) 2019-09-05 2020-11-03 腫瘍マーカーの一種であるａｑｕａｐｏｒｉｎ ２タンパク質とその応用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910850263.4A CN112535726B (zh) 2019-09-05 2019-09-05 一种肿瘤标志物aquaporin 2蛋白及其应用
CN201910850263.4 2019-09-05

Publications (2)

Publication Number Publication Date
WO2021043340A2 WO2021043340A2 (zh) 2021-03-11
WO2021043340A3 true WO2021043340A3 (zh) 2021-04-22

Family

ID=74852112

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/126029 WO2021043340A2 (zh) 2019-09-05 2020-11-03 一种肿瘤标志物aquaporin 2蛋白及其应用

Country Status (7)

Country Link
US (1) US20220299516A1 (zh)
EP (1) EP4006166A4 (zh)
JP (1) JP7323965B2 (zh)
CN (1) CN112535726B (zh)
AU (1) AU2020342299B2 (zh)
CA (1) CA3169749A1 (zh)
WO (1) WO2021043340A2 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002020787A1 (en) * 2000-09-09 2002-03-14 Goodgene Inc. Mutated aqp, method for detecting cancer using the same, dna chip having oligonucleotides of said mutated aqp sequence
WO2009031635A1 (ja) * 2007-09-07 2009-03-12 National University Corporation Nagoya University 腎性尿崩症治療用組換えベクター及びその用途
WO2013057599A1 (en) * 2011-10-17 2013-04-25 Socrates Tzartos Biomarker
CN103797131A (zh) * 2011-06-16 2014-05-14 卡里斯生命科学卢森堡控股有限责任公司 生物标志物组合物和方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2481334A1 (en) * 2002-04-01 2003-10-16 Anthony C. Stevens Tissue-specific endothelial membrane proteins
WO2006084027A2 (en) * 2005-02-02 2006-08-10 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Sipa-1 gene and sipa-1 inhibitor for the treatment, prevention, and diagnosis of cancer
ES2703363T3 (es) * 2008-02-01 2019-03-08 Massachusetts Gen Hospital Uso de microvesículas en el diagnóstico y pronóstico de tumores cerebrales
BR112014002857A2 (pt) * 2011-08-11 2017-02-21 Nat Univ Corp Tokyo Medical & Dental Univ método para pré-tratamento de amostras biológicas contendo proteína

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002020787A1 (en) * 2000-09-09 2002-03-14 Goodgene Inc. Mutated aqp, method for detecting cancer using the same, dna chip having oligonucleotides of said mutated aqp sequence
WO2009031635A1 (ja) * 2007-09-07 2009-03-12 National University Corporation Nagoya University 腎性尿崩症治療用組換えベクター及びその用途
CN103797131A (zh) * 2011-06-16 2014-05-14 卡里斯生命科学卢森堡控股有限责任公司 生物标志物组合物和方法
WO2013057599A1 (en) * 2011-10-17 2013-04-25 Socrates Tzartos Biomarker
EP2769220A1 (en) * 2011-10-17 2014-08-27 TZARTOS, Socrates Biomarker

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JENNIFER S. MYERS, VON LERSNER ARIANA K., ROBBINS CHARLES J., SANG QING-XIANG AMY: "Differentially Expressed Genes and Signature Pathways of Human Prostate Cancer", PLOS ONE, vol. 10, no. 12, pages e0145322, XP055400791, DOI: 10.1371/journal.pone.0145322 *
LIANG CHUN-LING; ZHANG PEI-CHUN; WU JUN-BIAO; LIU BI-HAO; YU-HE; LU RUI-RUI; JIE-ZHOU; ZHOU JIU-YAO: "Zhen-wu-tang attenuates Adriamycin-induced nephropathy via regulating AQP2 and miR-92b", BIOMEDICINE AND PHARMACOTHERAPY., ELSEVIER, FR, vol. 109, 1 January 1900 (1900-01-01), FR, pages 1296 - 1305, XP085552088, ISSN: 0753-3322, DOI: 10.1016/j.biopha.2018.10.146 *
REN CHUANCHUAN, FENGJINJIN, XIE JIA FENG, JIAZHIMING, YANSHAOHUA, ZHENG XIANGYU, WEN JIANGUO, WANG QIONG: "Expressions of Aquaporin 1-3 in Normal and Hydronephrotic Fetal Kidneys", CHINESE JOURNAL OF PEDIATRIC SURGERY, vol. 38, no. 10, 31 October 2017 (2017-10-31), pages 769 - 774, XP009527506, ISSN: 0253-3006 *

Also Published As

Publication number Publication date
CA3169749A1 (en) 2021-03-11
JP2022547097A (ja) 2022-11-10
EP4006166A4 (en) 2023-09-27
AU2020342299A1 (en) 2022-03-17
AU2020342299B2 (en) 2024-02-15
CN112535726B (zh) 2023-09-12
EP4006166A2 (en) 2022-06-01
US20220299516A1 (en) 2022-09-22
JP7323965B2 (ja) 2023-08-09
CN112535726A (zh) 2021-03-23
WO2021043340A2 (zh) 2021-03-11

Similar Documents

Publication Publication Date Title
MX2021006510A (es) Nanomotores impulsados por enzimas funcionalizados.
WO2016161410A3 (en) Treatment of cancer using inhibitors of tgf-beta and pd-1
CR20220317A (es) Anticuerpos anti-cd73 y usos de estos
WO2012153187A3 (en) Markers for cancer prognosis and therapy and methods of use
MX2019008503A (es) Receptores de antigenos quimericos contra axl o ror2 y metodos de uso de los mismos.
WO2003104399A3 (en) CANCER-RELATED GENE AS A TARGET IN CHEMOTHERAPY
MY200744A (en) Polypeptides antagonizing wnt signaling in tumor cells
MX2023005873A (es) Tratamiento del cancer.
WO2016191675A3 (en) Antibodies against glypican-3 and their uses in cancer diagnosis and treatment
WO2014198919A3 (en) Tumor marker, monoclonal antibodies and methods of use thereof
Stodulski et al. Parotid salivary duct carcinoma: a single institution’s 20-year experience
WO2011038142A3 (en) Bladder cancer specific ligand peptides
CA2949045A1 (en) Alpha-enolase specific antibodies and methods of uses in cancer therapy
MX2018009499A (es) Anticuerpos monoclonales especificos de egfl6 y metodos de su uso.
WO2009124281A3 (en) Novel antibodies against cancer target block tumor growth, angiogenesis and metastasis
WO2021081457A3 (en) Methods and agents for enhancing t cell therapies
ATE553112T1 (de) Ttk in der diagnose und als therapeutisches target bei krebs
WO2011051271A3 (en) Prostate tumor markers and methods of use thereof
WO2021043340A3 (zh) 一种肿瘤标志物aquaporin 2蛋白及其应用
WO2019027987A3 (en) COMPOSITIONS AND METHODS FOR TARGETING MASAS TO TREAT CANCERS WITH SPLICE COMPLEX MUTATIONS
MX2022000262A (es) Nuevos antigenos y metodos contra el cancer.
MX2021015766A (es) Nuevos antigenos y metodos contra el cancer.
MX2021002500A (es) Anticuerpos y secuencias de nucleotidos novedosos, y sus usos.
DE60226956D1 (de) Verstärktes krebs-gen wip1
RU2017136183A (ru) Полипептиды для лечения онкологических заболеваний

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20859995

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 20859995.1

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2022514787

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020859995

Country of ref document: EP

Effective date: 20220224

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020342299

Country of ref document: AU

Date of ref document: 20201103

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3169749

Country of ref document: CA